| Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development M Frantzi, A Bhat, A Latosinska Clinical and translational medicine 3, 1-22, 2014 | 149 | 2014 |
| Profilin 1 is a potential biomarker for bladder cancer aggressiveness J Zoidakis, M Makridakis, PG Zerefos, V Bitsika, S Esteban, M Frantzi, ... Molecular & cellular proteomics 11 (4), 2012 | 125 | 2012 |
| Development and validation of urine-based peptide biomarker panels for detecting bladder cancer in a multi-center study M Frantzi, KE Van Kessel, EC Zwarthoff, M Marquez, M Rava, N Malats, ... Clinical Cancer Research 22 (16), 4077-4086, 2016 | 105 | 2016 |
| Peptidomics and proteomics based on CE‐MS as a robust tool in clinical application: The past, the present, and the future A Latosinska, J Siwy, H Mischak, M Frantzi Electrophoresis 40 (18-19), 2294-2308, 2019 | 96 | 2019 |
| Proteomics and metabolomics for AKI diagnosis D Marx, J Metzger, M Pejchinovski, RB Gil, M Frantzi, A Latosinska, ... Seminars in nephrology 38 (1), 63-87, 2018 | 86 | 2018 |
| Discovery and validation of urinary biomarkers for detection of renal cell carcinoma M Frantzi, J Metzger, RE Banks, H Husi, J Klein, M Dakna, W Mullen, ... Journal of proteomics 98, 44-58, 2014 | 79 | 2014 |
| Developing proteomic biomarkers for bladder cancer: towards clinical application M Frantzi, A Latosinska, L Flühe, MC Hupe, E Critselis, MW Kramer, ... Nature Reviews Urology 12 (6), 317-330, 2015 | 78 | 2015 |
| Proteomics biomarkers for solid tumors: Current status and future prospects I Belczacka, A Latosinska, J Metzger, D Marx, A Vlahou, H Mischak, ... Mass spectrometry reviews 38 (1), 49-78, 2019 | 73 | 2019 |
| Proteomics in drug development: the dawn of a new era? M Frantzi, A Latosinska, H Mischak PROTEOMICS–Clinical Applications 13 (2), 1800087, 2019 | 55 | 2019 |
| Biomarkers for bladder cancer aggressiveness M Frantzi, M Makridakis, A Vlahou Current opinion in urology 22 (5), 390-396, 2012 | 44 | 2012 |
| Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: focus on bladder cancer A Latosinska, M Frantzi, A Vlahou, H Mischak Proteomics–Clinical Applications 7 (11-12), 779-793, 2013 | 38 | 2013 |
| Proteome‐based classification of nonmuscle invasive bladder cancer R Stroggilos, M Mokou, A Latosinska, M Makridakis, V Lygirou, ... International Journal of Cancer 146 (1), 281-294, 2020 | 37 | 2020 |
| Urinary CE-MS peptide marker pattern for detection of solid tumors I Belczacka, A Latosinska, J Siwy, J Metzger, AS Merseburger, H Mischak, ... Scientific reports 8 (1), 5227, 2018 | 36 | 2018 |
| Proteomics analysis of bladder cancer invasion: targeting EIF3D for therapeutic intervention A Latosinska, M Mokou, M Makridakis, W Mullen, J Zoidakis, V Lygirou, ... Oncotarget 8 (41), 69435, 2017 | 31 | 2017 |
| Clinical proteomics for precision medicine: the bladder cancer case A Latosinska, M Frantzi, A Vlahou, AS Merseburger, H Mischak PROTEOMICS–Clinical Applications 12 (2), 1700074, 2018 | 30 | 2018 |
| Urinary glycopeptide analysis for the investigation of novel biomarkers I Belczacka, M Pejchinovski, M Krochmal, P Magalhães, M Frantzi, ... PROTEOMICS–Clinical Applications 13 (3), 1800111, 2019 | 27 | 2019 |
| Clinical proteomics: Closing the gap from discovery to implementation M Frantzi, A Latosinska, G Kontostathi, H Mischak Proteomics 18 (14), 1700463, 2018 | 27 | 2018 |
| CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer M Frantzi, E Gomez Gomez, A Blanca Pedregosa, J Valero Rosa, ... British journal of cancer 120 (12), 1120-1128, 2019 | 26 | 2019 |
| Drug repurposing in oncology M Frantzi, A Latosinska, M Mokou, H Mischak, A Vlahou The Lancet Oncology 21 (12), e543, 2020 | 25 | 2020 |
| Ten years of proteomics in bladder cancer: progress and future directions M Frantzi, A Vlahou Bladder Cancer 3 (1), 1-18, 2017 | 25 | 2017 |
